[Concurrent] Zhu Jingjin, President of Biological Products Division of Sinopharm Group
We know that the development of vaccines has higher requirements and stricter quality standards than the development of conventional drugs. Generally speaking, it takes at least 5 to 10 years for a vaccine to be developed to market.
[Concurrent] Hu Yaling, Deputy General Manager of Beijing Kexing Zhongwei Biotechnology Co., Ltd.
Starting from January of 2020, we have maintained a tense state of standing by all the time.
【Subtitles】New Coronary Pneumonia Cases Found in Wuhan in December 2019
China launches new crown vaccination work on New Year's Day 2021
1. January 1: 9 key groups of people start to receive the new crown vaccine;
2. January 13: More than 10 million doses of vaccination;
3. Around the Spring Festival: vaccinations for 18-60 year olds in various places;
4. Late March: People over 60 years old will start vaccination;
5. March 27: The number of inoculation doses exceeded 100 million;
June and April: Foreign nationals, Hong Kong, Macao and Taiwan residents will be vaccinated successively in various places;
7. May 7th: WHO will include Sinopharm's new crown vaccine on the emergency use list;
[Concurrent] Zhu Jingjin, President of Biological Products Division of Sinopharm Group
This is the first emergency use certification of China's new crown vaccine approved by the WHO and the first developing country new crown vaccine approved by the WHO.
8. May 23: The number of inoculation doses exceeded 500 million;
9. May 28: The number of inoculation doses exceeded 600 million, and the 500-600 million doses took only 5 days;
10. June: Approval of the emergency use of the new crown inactivated vaccine for people aged 3-17;
11. June 19: The number of inoculation doses exceeded 1 billion;
12. June 20: Shenzhen announced that several local cases were infected with the Delta mutant strain;
[Concurrent] Zhang Yuntao, Vice President, Chief Scientist of China Biology
The delta strain makes many vaccines a little off target, some breakthrough cases will occur, and protection cases will drop.
[Concurrent] Hu Yaling, Deputy General Manager of Beijing Kexing Zhongwei Biotechnology Co., Ltd.
Every time this sudden wave of new epidemics, or the emergence of a new mutant strain, it will affect everyone's hearts, and then pay attention to our current vaccine prevention and control strategies.
13. As of early July: More than 100 countries have approved the use of Chinese vaccines;
14. September 15: Over 1 billion people completed the entire vaccination process;
15. October: Intensified injections will be vaccinated successively in various places;
[Concurrent] Yang Guang, Chief Commercial Officer of Kexing Holdings Biotechnology Co., Ltd.
In the past, the annual production volume of vaccines in China was almost hundreds of millions of doses.
Then in fact, with the development of research and the gradual development of the epidemic, basically we are in such a state of continuous rotation for 24 hours. At present, we can actually supply 3 to 4 billion doses according to statistics, so in terms of the supply of the third injection We must also be able to guarantee it.
16. November 9: The Omi Keron mutant was detected for the first time in South Africa;
[Concurrent] Zhang Yuntao, Vice President, Chief Scientist of China Biology
We use the Omi Keron strain to develop a new generation of inactivated vaccines against the Omi Keron strain as an alternative to be considered when strengthening the injection in the future. This is the development of inactivated vaccines; at the same time, our recombinant protein vaccines are also launched. The genetic map design of the Omi Keron strain was designed.
[Concurrent] Hu Yaling, Deputy General Manager of Beijing Kexing Zhongwei Biotechnology Co., Ltd.
In fact, every time a new mutant strain appears, we have made a vaccine.
From beta, gamma, delta, and now Omi Keron, this is enough to support us in the rapid switch of vaccines.
17. November 19: The coverage rate of vaccinated population exceeds 80%;
18. As of early December: 8 billion doses of vaccines have been vaccinated globally, of which Chinese vaccines play an important role;
[Concurrent] Yang Guang, Chief Commercial Officer of Kexing Holdings Biotechnology Co., Ltd.
As of the end of November, Kexing has supplied more than 2.3 billion doses of vaccine to the world.
There should be nearly 2 billion doses of inoculations from Kexing.
[Concurrent] Liu Jingzhen, Chairman of Sinopharm Group
Sinopharm China Bio-New Crown Inactivated Vaccine is registered and approved for use in 112 countries and international organizations around the world.
19. As of December 20: 269,581 million doses of vaccination
20. Get vaccinated to fight the epidemic, we will not stop...
[Concurrent] Hu Yaling, Deputy General Manager of Beijing Kexing Zhongwei Biotechnology Co., Ltd.
When new mutant strains appear, we can quickly complete early virus seed screening, process adaptability evaluation and large-scale mass production in a short period of time. This is a relatively complete development that we have formed in the past year.的系统。 The system.
[Subtitle] China Kexing's annual production capacity currently reaches 2 billion doses, with a monthly supply of up to 400 million doses.
[Concurrent] Zhu Jingjin, President of Biological Products Division of Sinopharm Group
China Biosciences is accelerating the research and development of other technical routes for vaccines.
In the new crown inactivated vaccine, we have achieved a breakthrough of "from 0 to 1", and now we are working hard for the goal of "from 1 to N".
[Subtitle] Sinopharm Group China Biotech's overall annual production capacity reaches 7 billion yuan, and it plans to increase it to 10 billion yuan in the near future.
Reporter Wen Mengxin reports from Beijing
Editor in charge: [Li Yuxin]